News Archive

Johns Hopkins University has won a key court judgement in its disputed plan to develop a 108-acre donated farm into a $4.7 million “science city,” The Gazette reports.

The Maryland Court of Special Appeals ruled Thursday that the plan complies with the agreement forged between Johns Hopkins and Elizabeth Banks, who sold Belward Farm in 1989 for $5 million. In November 2011, Tim Newell, one of Banks’ relatives, sued Hopkins claiming the university was violating a land use agreement it made with Banks.

The state of Maryland and NASA’s Goddard Space Flight Center in Greenbelt, Md., have embarked on a new partnership effort, the main goal of which is to attract high technology companies to Maryland, which in turn will enable both future missions of NASA and the economic future of Maryland. The agreement, signed by U.S. Sen. Barbara Mikulski, Maryland Gov. Martin O’Malley and Goddard Space Flight Center Director Chris Scolese will help in several ways. Goddard will obtain specialized skills and technologies needed for its numerous mission applications. It will help the center engage in technical exchanges with local tech companies regarding new trends, theories, techniques and problems in aerospace technology. And finally, it will provide an opportunity for the development of local educational and labor resources specific to Goddard’s needs.

Baltimore is a top destination for students looking to attend college.

The Charm City has ranked eighth among major metro areas in the American Institute for Economic Research’s College Destinations Index for 2013 and 2014.

‘We need to provide high-quality education at a lower cost. If at the end of the day, this means there aren’t as many universities or some people don’t have jobs, you know, this is not a welfare business. We have the interest of the nation at stake. And this is what we all have to keep focused on—high quality and containing costs.’

William E. Kirwan, Chancellor, University

Dr. Daniel Saltzman says he can prove that bacteria that ordinarily cause food poisoning in people can be modified for use as guided missiles to deliver cancer-killing payloads into tumors.

But he needs $500,000 for some preliminary work, and despite his project’s potential, he’s not holding his breath for funding from the National Institutes of Health (NIH), the nation’s leading source of biomedical research grants.

As reported in the Baltimore News Journal, Baltimore County Executive Kevin Kamenetz on Monday proposed a new department name and department head nominee for the County’s economic development agency.

QIAGEN has announced an agreement with Eli Lilly and Company to develop and commercialize a molecular companion diagnostic paired with a novel Lilly oncology compound. This is the third co-development project by QIAGEN and Lilly to create companion diagnostics, which are tests that analyze genomic information in patient samples to enable personalized decisions on treatments.  

The latest collaboration, involving an undisclosed Lilly compound and an undisclosed molecular diagnostic target, builds on a master collaboration agreement for development of tailored therapies in cancer and other therapeutic areas signed earlier this year.

Before 1960, the only way to treat cardiac arrest involved opening up the chest cavity and applying manual cardiac massage. The surgeon would take the heart in his hands and squeeze it ever so cautiously to a distinct rhythm in order to help pump blood to the brain and other important organs, giving the patient a chance at life once again. While a bold method, it was rarely attempted and more often than not didn’t prove successful.

So, taking this as an opportunity to try something new, surgeons at Johns Hopkins created a new Cardiopulmonary Resuscitation technique dubbed closed-chest cardiac massage. The group of surgeons with a knack for innovation created a way to pump the arrested heart without ever having to open up the patient.

GlaxoSmithKline’s $500 million portfolio with Avalon Ventures invested in its in first startup – Palo Alto-based Sitari Pharmaceuticals.

According to Fierce Biotech, the San Diego-based venture group and its partners at GSK are funding Sitari with $10 million in cash and research support, with the R&D assist coming from the pharma giant.